Autopsy report · NCT00628264
Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery
Cause of deathSlow enrollment
“The study was terminated due to a considerably lower recruitment rate than anticipated”
Life of this trial
- Ran for about 1 year 3 months before it stopped.
- 75 participants planned (an estimate, not an actual count).
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Action Pharma A/S
- Sponsor type
- Industry
- Conditions
- Cardiac Surgery; Coronary Artery Bypass Grafting; Valve Surgery; Kidney Injury
- Interventions
- AP214; Placebo
- Participants
- 75 (planned, not actual)
- Sites
- 2
- Countries
- United States
Trials that died the same way
- Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children
“Due to low recruitment numbers, the study was terminated.” - Alfuzosin Versus Placebo in Acute Urinary Retention
“The study was early terminated due to slow and difficult recruitment” - Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
“The study was terminated due to recruitment challenges” - Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab
“Study was terminated early because of slow recruitment” - The Effect of Ovamax on Oocyte Quality
“The study was stopped prematurely due to low recruitment rate”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.